The company has rededicated itself to a fully blood-based test pipeline, with its next assays focused on women's health, including endometriosis and ovarian, uterine, and cervical cancers.
The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.
Using enhancements to RT-PCR, the firm is able to detect all protein-coding genes in a single-tube multiplex reaction, reducing costs for large-scale projects.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
The test is the fifth assay on the Solana platform to obtain clearance, and expands the firm's offerings in the women's health market.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.